Bromantane for Health & Longevity - Quick Reference Sheet

Bromantane for Health & Longevity

Created on 10/14/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Wonder 1.0 – Audit

Bromantane is a laboratory-made oral medication developed in Russia for persistent weakness and exhaustion and for sustaining capacity under strain. Human evidence is narrow and comes mainly from diagnosed patients; studies in healthy adults are few. Harms in short courses appear uncommon and non-serious in the published series, with activation and disturbed sleep the main concerns. Longer use, older age, pregnancy and combined stimulant use remain essentially unstudied. (Full Review)

Protocol

Studied daily dose
Fifty to one hundred milligrams daily
For twenty-eight days in the open multicentre asthenia series
Time of day
Morning administration
Final dose before late afternoon because of activation and sleep effects
Single or split dose
One hundred to two hundred milligrams across two daytime doses
Russian product descriptions; the cited clinical series reports only the daily total
Time to effect
Reduced asthenic symptoms in neurasthenia and related asthenia
From day three
Open multicentre series; benefit persisting one month after stopping
Reduced anxiety alongside stimulation in asthenic disorders
During twenty-eight days
Anxiety-reducing effects were reported during twenty-eight days in asthenic disorders
Psychophysiological performance during mental fatigue
After a single dose
One hundred milligrams once in volunteers during fatigue

Benefits

Contraindications
  • Pregnancy and breastfeeding
  • Children and adolescents up to 18 years
  • Athletes subject to anti-doping testing
  • Current mania or psychosis (theoretical)
  • Known hypersensitivity (immune over-reaction) to bromantane or its formulation components
Key Interactions
  • Monoamine oxidase inhibitors (antidepressants blocking dopamine breakdown; phenelzine, tranylcypromine, selegiline): Avoid (theoretical)
  • Prescription stimulants (methylphenidate, amphetamine salts, modafinil): Caution (theoretical)
  • Dopamine-blocking antipsychotic medications (haloperidol, risperidone, olanzapine): Caution (theoretical)
  • Levodopa and dopamine agonists (medications replacing or mimicking dopamine; pramipexole, ropinirole): Caution (theoretical)
  • Serotonergic antidepressants (antidepressants acting on serotonin, a brain messenger involved in mood and sleep; sertraline, fluoxetine, venlafaxine): Monitor (theoretical)
  • Benzodiazepines and sedating medications (calming or sleep medications; lorazepam, zolpidem): Monitor (theoretical)
  • Medications cleared by cytochrome P450 liver enzymes (simvastatin, amlodipine, sertraline): Monitor (theoretical)
  • Over-the-counter stimulants and decongestants (caffeine products, pseudoephedrine): Caution (theoretical)
  • Supplements raising dopamine or stimulation (L-tyrosine, mucuna, high-dose caffeine, yohimbine): Caution (theoretical)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Treatment discontinuation during short-term clinical use; Excessive activation and disturbed sleep; Allergic reaction
  • Speculative: Dependence or long-term dopamine adaptation; High-dose neurological and bodily toxicity; Reproductive and developmental effects

Monitoring

Marker Target Why
Systolic and diastolic blood pressure No established target — track change from the individual baseline Safety check for cardiovascular activation
Resting heart rate 60–100 beats per minute (standard reference range) Safety check for cardiovascular activation
Alanine aminotransferase 7–56 units per litre (standard reference range) Safety check during hepatic metabolism

Cadence: Baseline before any course; blood pressure, heart rate and sleep records repeated at one week and four weeks, with liver testing repeated at four weeks when baseline values or symptoms warrant it

Qualitative Assessment

  • Sleep onset, awakenings and morning restoration
  • Daytime energy and motivation across the working day
  • Anxiety, irritability and any elevation of mood or speech pressure
  • Sustained work capacity under mental fatigue